Background
Methods
Data source
Study population and study design
Outcomes
Statistical analysis
Results
Study population
Total | BT-naïve | BT-experienced | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ADL | IFX | SCK | UST | Sub total | ADL | IFX | SCK | UST | Sub total | ADL | IFX | SCK | UST | Sub total | |
Number of patients | 42 | 52 | 21 | 90 | 205 | 37 | 48 | 13 | 79 | 177 | 5 | 4 | 8 | 11 | 28 |
Average Age | 50.0 | 46.2 | 45.4 | 46.8 | 47.1 | 50.9 | 46.0 | 46.2 | 46.5 | 47.3 | 43.4 | 47.5 | 44.3 | 48.4 | 46.2 |
% Female | 7.1% | 21.2% | 33.3% | 17.8% | 18.1% | 8.1% | 20.8% | 46.2% | 20.3% | 19.8% | 0.0% | 25.0% | 12.5% | 0.0% | 7.1% |
ADL | IFX | SCK | UST | Total | |
---|---|---|---|---|---|
Number of patients | 42 (100%) | 52 (100%) | 21 (100%) | 90 (100%) | 205 (100%) |
Obesity | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 1 (0.5%) |
Diabetes without complication/comorbidity | 2 (4.8%) | 4 (7.7%) | 0 (0%) | 6 (6.7%) | 12 (5.9%) |
Diabetes with complication/comorbidity | 0 (0%) | 2 (3.8%) | 1 (4.8%) | 4 (4.4%) | 7 (3.4%) |
Hypertension | 6 (14.3%) | 11 (21.2%) | 4 (19.0%) | 28 (31.1%) | 49 (23.9%) |
Hyperlipidemia | 8 (19.0%) | 13 (25.0%) | 5 (23.8%) | 20 (22.2%) | 46 (22.4%) |
Subsequent/old myocardial infarction | 0(0%) | 1 (1.9%) | 0(0%) | 1 (1.1%) | 2 (1.0%) |
Heart failure | 2 (4.8%) | 4 (7.7%) | 0 (0%) | 8 (8.9%) | 14 (6.8%) |
Persistence rates
Total | BT-naïve | |||||||
---|---|---|---|---|---|---|---|---|
ADL | IFX | SCK | UST | ADL | IFX | SCK | UST | |
Number of patients | 42 | 52 | 21 | 90 | 37 | 48 | 13 | 79 |
12-month persistence rate ± 95% CI | 45.9% ± 15.5% | 53.1% ± 14.7% | 74.2% (95% CI not available) | 79.8% ± 9.1% | 46.8% ± 16.6% | 53.0% ± 14.9% | 55.4% (95% CI not available) | 79.4% ± 9.9% |
24-month persistence rate ± 95% CI | 45.9 ± 15.5% | 41.1% ± 15.4% | 74.2% (95% CI not available) | 73.4% ± 10.9% | 46.8 ± 16.6% | 41.0% ± 15.5% | 55.4% (95% CI not available) | 71.9 ± 12.2% |
p-value of log-rank test (versus UST) | < 0.001 | < 0.001 | 0.254 | – | < 0.001 | < 0.001 | 0.006 | – |
p-value of wilcoxon test (versus UST) | < 0.001 | 0.001 | 0.163 | – | < 0.001 | 0.001 | 0.004 | – |
Medical costs
Total | BT-naïve | ||||||||
---|---|---|---|---|---|---|---|---|---|
ADL | IFX | UST | Sub total | ADL | IFX | UST | Subtotal | ||
Number of patients | 18 | 20 | 37 | 77 | 14 | 19 | 30 | 64 | |
Average Age | 47.7 | 46.5 | 46.2 | 46.8 | 49.6 | 47.3 | 46.3 | 47.5 | |
%Female | 11.1% | 20.0% | 16.2% | 15.6% | 14.3% | 21.1% | 20.0% | 18.8% | |
Cost (pre) | ¥760 | ¥950 | ¥900 | ¥886 | ¥365 | ¥916 | ¥603 | ¥641 | |
In 1000 JPY unit | IP | ¥18 | ¥343 | ¥254 | ¥235 | ¥0 | ¥361 | ¥162 | ¥188 |
OP | ¥513 | ¥301 | ¥425 | ¥405 | ¥133 | ¥261 | ¥216 | ¥210 | |
RX | ¥229 | ¥306 | ¥221 | ¥246 | ¥232 | ¥294 | ¥225 | ¥244 | |
Cost increase | ¥1538 | ¥2429 | ¥1865 | ¥1907 | ¥1853 | ¥2494 | ¥2221 | ¥2187 | |
In 1000 JPY unit | IP | ¥95 | ¥601 | - ¥37 | ¥156 | ¥146 | ¥633 | ¥21 | ¥228 |
OP | ¥1077 | ¥1958 | ¥2011 | ¥1754 | ¥1379 | ¥1974 | ¥2296 | ¥1965 | |
RX | ¥366 | - ¥130 | - ¥109 | - ¥2 | ¥328 | - ¥113 | - ¥96 | - ¥5 |
Total | BT-naïve | ||||||||
---|---|---|---|---|---|---|---|---|---|
ADL | IFX | UST | Sub total | ADL | IFX | UST | Sub total | ||
Number of patients | 6 | 6 | 29 | 42 | 4 | 6 | 23 | 33 | |
Average Age | 50.8 | 44.7 | 45.0 | 46.0 | 54.0 | 44.7 | 44.8 | 45.9 | |
%Female | 16.7% | 16.7% | 17.2% | 16.7% | 25.0% | 16.7% | 21.7% | 21.2% | |
Cost (pre) | ¥1092 | ¥1062 | ¥925 | ¥988 | ¥360 | ¥1062 | ¥597 | ¥653 | |
In 1000 JPY unit | IP | ¥55 | ¥603 | ¥315 | ¥340 | ¥0 | ¥603 | ¥201 | ¥250 |
OP | ¥876 | ¥398 | ¥418 | ¥473 | ¥263 | ¥398 | ¥211 | ¥251 | |
RX | ¥161 | ¥61 | ¥192 | ¥175 | ¥97 | ¥61 | ¥186 | ¥152 | |
Cost increase | ¥1606 | ¥2246 | ¥1875 | ¥1883 | ¥2433 | ¥2246 | ¥2211 | ¥2244 | |
In 1000 JPY unit | IP | - ¥55 | - ¥174 | - ¥147 | - ¥140 | ¥0 | - ¥174 | - ¥98 | - ¥100 |
OP | ¥1365 | ¥2446 | ¥2114 | ¥2054 | ¥2461 | ¥2446 | ¥2380 | ¥2402 | |
RX | ¥295 | - ¥26 | - ¥91 | - ¥30 | - ¥27 | - ¥26 | - ¥71 | - ¥57 |
Total | BT-naïve | ||||||||
---|---|---|---|---|---|---|---|---|---|
ADL | IFX | UST | Sub total | ADL | IFX | UST | Subtotal | ||
Number of patients | 12 | 14 | 8 | 35 | 10 | 13 | 7 | 31 | |
Average Age | 46.1 | 47.3 | 50.5 | 47.8 | 47.9 | 48.5 | 51.1 | 49.1 | |
%Female | 8.3% | 21.4% | 12.5% | 14.3% | 10.0% | 23.1% | 14.3% | 16.1% | |
Cost (pre) | ¥595 | ¥902 | ¥808 | ¥762 | ¥367 | ¥848 | ¥621 | ¥629 | |
In 1000 JPY unit | IP | ¥0 | ¥231 | ¥32 | ¥108 | ¥0 | ¥249 | ¥36 | ¥122 |
OP | ¥332 | ¥259 | ¥448 | ¥324 | ¥81 | ¥198 | ¥232 | ¥166 | |
RX | ¥263 | ¥412 | ¥328 | ¥330 | ¥286 | ¥401 | ¥353 | ¥341 | |
Cost increase | ¥1504 | ¥2507 | ¥1828 | ¥1937 | ¥1620 | ¥2608 | ¥2254 | ¥2126 | |
In 1000 JPY unit | IP | ¥170 | ¥933 | ¥362 | ¥511 | ¥204 | ¥1005 | ¥414 | ¥577 |
OP | ¥932 | ¥1749 | ¥1638 | ¥1395 | ¥946 | ¥1756 | ¥2021 | ¥1499 | |
RX | ¥402 | - ¥175 | - ¥172 | ¥31 | ¥470 | - ¥153 | - ¥181 | ¥50 |
ADL | IFX | UST | Total | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P | NP | Δ | P | NP | Δ | P | NP | Δ | P | NP | Δ | ||
Number of patients | 4 | 10 | 6 | 13 | 23 | 7 | 33 | 31 | |||||
Cost (pre) | ¥360 | ¥367 | ¥7 | ¥1062 | ¥848 | - ¥214 | ¥597 | ¥621 | ¥24 | ¥653 | ¥629 | - ¥24 | |
In 1000 JPY unit | IP | ¥0 | ¥0 | ¥0 | ¥603 | ¥249 | - ¥354 | ¥201 | ¥36 | - ¥165 | ¥250 | ¥122 | - ¥128 |
OP | ¥263 | ¥81 | - ¥182 | ¥398 | ¥198 | - ¥200 | ¥211 | ¥232 | ¥21 | ¥251 | ¥166 | - ¥85 | |
RX | ¥97 | ¥286 | ¥189 | ¥61 | ¥401 | ¥340 | ¥186 | ¥353 | ¥167 | ¥152 | ¥341 | ¥189 | |
Cost (increase) | ¥2433 | ¥1621 | - ¥812 | ¥2246 | ¥2608 | ¥362 | ¥2211 | ¥2254 | ¥43 | ¥2244 | ¥2126 | -¥118 | |
In 1000 JPY unit | IP | ¥0 | ¥204 | ¥204 | -¥174 | ¥1005 | ¥1179 | -¥98 | ¥414 | ¥512 | -¥100 | ¥577 | ¥677 |
OP | ¥2460 | ¥946 | - ¥1514 | ¥2446 | ¥1756 | -¥690 | ¥2380 | ¥2021 | -¥359 | ¥2402 | ¥1499 | -¥903 | |
RX | -¥27 | ¥471 | ¥498 | -¥26 | -¥153 | -¥127 | -¥71 | -¥180 | -¥109 | -¥57 | ¥50 | ¥107 |